PHP
OVID icon

Parkman Healthcare Partners’s Ovid Therapeutics OVID Stock Holding History

Parkman Healthcare Partners’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532K Sell
197,947
-10,258
-5% -$26.5K 0.05% 76
2026
Q1 		$462K Buy
208,205
+7,169
+4% +$12.8K 0.05% 88
2025
Q4 		$328K Sell
201,036
-1,942
-1% -$2.99K 0.03% 100
2025
Q3 		$264K Buy
+202,978
New +$176K 0.03% 91

Other funds holding OVID

Jupiter Topco
Jupiter Topco New York $245B AUM
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Parkman Healthcare Partners's OVID Position: Q2 2026 in Review

Parkman Healthcare Partners reduced its Ovid Therapeutics (OVID) stake by 4.9% in Q2 2026, selling an estimated $26.5K and leaving 197,947 shares worth $532K. The position accounts for 0.05% of the portfolio, ranked #76.

Parkman Healthcare Partners first reported a position in OVID in Q3 2025 and has held it in 4 quarters since. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Parkman Healthcare Partners held 197,947 shares of Ovid Therapeutics worth $532K as of Q2 2026.
  • Parkman Healthcare Partners sold 10,258 Ovid Therapeutics shares in Q2 2026, an estimated $26.5K.
  • Ovid Therapeutics made up 0.05% of Parkman Healthcare Partners's portfolio in Q2 2026, its #76 holding.
  • Parkman Healthcare Partners first reported a position in Ovid Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.